# GLP-1s in People Being Treated for Cancer

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-10-30

Canonical page: https://glpwatchdog.org/research/glp1s-in-people-being-treated-for-cancer

> Lower mortality and fewer hospitalizations than metformin, at a hazard ratio of 0.875. A second comparison against insulin produced a bigger number, and the bigger number is the less trustworthy one.

## Key points

- Mortality HR 0.875 vs metformin: modest, and the believable comparison.
- 0.786 vs insulin, which marks sicker, longer-standing diabetes. The bigger effect, worse comparison.
- Lower hospitalization, sepsis, MACE, pulmonary embolism and pneumonia.
- Subanalyses by BMI and HbA1c did not reach significance, so neither explanation is confirmed or ruled out.

People with both diabetes and cancer who took GLP-1 drugs had lower all-cause mortality and fewer hospitalizations than those on metformin, with a hazard ratio of **0.875**.[1] A second analysis, comparing people newly started on a GLP-1 against people newly started on insulin, produced a bigger number. The choice of comparator is a reason to be suspicious of it.

## What was found

*All-cause mortality in patients with diabetes and cancer, by comparison group.*

| Comparison | Hazard ratio |
| --- | --- |
| GLP-1 vs metformin (monotherapy setting) | 0.875 (95% CI 0.778–0.985), p=0.0268 |
| Newly started GLP-1 vs newly started insulin | 0.786 (95% CI 0.662–0.934), p=0.0062 |

Secondary analyses found lower rates of all-cause hospitalization, sepsis, major adverse cardiovascular events, pulmonary embolism and pneumonia. Subanalyses stratified by body mass index and HbA1c did not reach statistical significance.[1]

## Which number to trust

The metformin comparison is the more believable one, and it is the smaller. Metformin is typically first-line and given to people whose diabetes is relatively well controlled, which makes them a reasonably fair comparison group.

Insulin is not. Being on insulin usually marks longer-standing, harder-to-control diabetes and more complications. Comparing a GLP-1 against insulin measures, in part, how sick each group already was before anyone counted a death.

> Against insulin the hazard ratio was 0.786; against metformin, the fairer comparison, it was 0.875.

We covered this at length in [the cancer cohorts article](https://glpwatchdog.org/research/glp1-and-cancer-risk-what-the-cohorts-show), where a study reported 91% lower breast cancer mortality against insulin users and *nothing at all* against a modern comparator in the same paper. The same bias is at work here, but the effect size is far more modest, which is itself reassuring about this study’s quality. Studying people without diabetes removes that comparator problem, though [a cohort that did so](https://glpwatchdog.org/research/cancer-risk-in-people-without-diabetes) followed people for a median of only two years.

## The subanalyses that failed

Stratifying by BMI and HbA1c did not reach significance.[1] That matters because it leaves the two most obvious explanations for how the drug might help, weight loss and glycemic control, neither confirmed nor ruled out. If the benefit were driven by either, you would expect it to track them, and these subanalyses could not show whether it does.

It may simply be that those subgroups were too small to show anything. But it means the study cannot tell you *why* the association exists, only that it does, in a design that cannot establish causation anyway.

## What this changes for a patient

- **Nothing on its own.** No GLP-1 is indicated for cancer, and the authors call for prospective, well-controlled studies. What else has been published for people after cancer is collected in [ten studies on GLP-1s after cancer](https://glpwatchdog.org/research/lists/top-glp1-cancer-survivor-outcomes-studies).
- **It is reassuring about continuation.** People with diabetes who develop cancer often wonder whether to stop everything metabolic. This does not suggest harm.
- **The hospitalization and infection findings are relevant to cancer care specifically**, where sepsis and pneumonia are major causes of treatment interruption. That is consistent with [the infection study](https://glpwatchdog.org/research/glp1-pneumonia-and-sepsis-risk), here seen in a much sicker population.
- **It belongs with the oncologist**, who is weighing appetite, nutrition and treatment tolerance in a way no general finding addresses.

> **One caution specific to this population.** Appetite suppression is not neutral during cancer treatment, where maintaining weight and nutritional status is often part of the treatment plan rather than a side issue. Fertility-sparing treatment of endometrial cancer is the reverse case, where [weight loss is part of the plan and semaglutide has been compared with surgery](https://glpwatchdog.org/research/the-group-that-lost-least-did-best). Any decision about a GLP-1 during active cancer therapy is a conversation with the team managing that treatment, not a conclusion from a mortality hazard ratio.

## Frequently asked questions

### Do GLP-1 drugs improve survival in people with cancer?

An observational study of people with both diabetes and cancer found lower all-cause mortality on GLP-1 drugs than on metformin, with a hazard ratio of 0.875, plus fewer hospitalizations, sepsis and cardiovascular events. It cannot establish cause, and the authors call for prospective studies.

### Why was the effect bigger against insulin?

Because insulin marks longer-standing, harder-to-control diabetes with more complications. Comparing against insulin users measures partly how sick each group already was. The metformin comparison is fairer and produces the smaller, more believable number.

### Is the benefit from weight loss?

The study cannot say. Subanalyses stratified by BMI and HbA1c did not reach statistical significance, so those two explanations are neither confirmed nor ruled out; the subgroups may simply have been too small.

### Should someone with cancer keep taking their GLP-1?

That belongs with the oncology team. Appetite suppression is not neutral during cancer treatment, where maintaining weight and nutritional status is often part of the plan. Nothing here suggests harm, and nothing here is a reason to start or continue without that conversation.

### Why do the infection findings matter here?

Because sepsis and pneumonia are major causes of interrupted cancer treatment. Lower rates of both, in a population this sick, are consistent with a separate and better-designed study of infection risk in diabetes.

## References

1. Mahadevan A, Vosooghi A, Arora JS, et al. GLP-1 receptor agonists in patients with cancer are associated with reduced all-cause mortality and hospitalization. The Journal of Clinical Endocrinology and Metabolism. 2026. PMID: 41482652. https://pubmed.ncbi.nlm.nih.gov/41482652/

---

Cite as: GLP Watchdog, Nora Bissett, "GLP-1s in People Being Treated for Cancer", published 2026-08-19, updated 2026-10-30. https://glpwatchdog.org/research/glp1s-in-people-being-treated-for-cancer

Canonical HTML page: https://glpwatchdog.org/research/glp1s-in-people-being-treated-for-cancer

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
